AI vs Rheumatologist? The Better Answer May Be Both Can artificial intelligence answer patients’ rheumatology questions as well as a rheumatologist? Abstract 2965 at #ACR26 suggests the answer may be yes, but also highlights why physician oversight still matters. https://t.co/RNbCUFjMQo

Why Did the Last Drug Fail? When a patient fails a drug, we tend to consider what will be the next drug. Most of our clinics have patients on their second or third advanced therapy. Drug failure has become more common, not less. A question that we too rarely write in the notes https://t.co/r5mQjI79iQ

Looking for RA-ILD: 9 Clinical Clues from ANCHOR-RA Which of our RA patients will develop RA-ILD, and how can we better identify these patients? In abstract #2884 at #ACR26 , Dr. Jeffrey Sparks presented findings from ANCHOR-RA trial, a large prospective cross-sectional study https://t.co/P96KAcPmWt

It was a beautiful Year in Preview from @AlexisOgdie - here's a summary of her take on what might be to come in rheumatology in the year ahead #ACR26 @RheumNow https://t.co/DneNoUkc7u https://t.co/jlAdwZYAQI

Making the Case for Early Biologics in Lupus A new diagnosis of SLE can be overwhelming for patients. The decision to initiate biologic versus non-biologic therapy early in the disease course may have far-reaching implications for disease control, glucocorticoid exposure, and https://t.co/CmTeHTwzZw

ACR 2026 Day 3 Report https://t.co/7DbbFhEtp4 https://t.co/tCB9tKgTup

Pregnancy After CAR-T in Autoimmune Disease: 14 Pregnancies, No Flares The first multicenter series of pregnancies after CAR T-cell therapy for autoimmune disease reports 8 healthy births and no maternal flares. It is the first dataset of its kind, and the numbers are small. https://t.co/uqWz8GeAmX

Menopause and Rheumatoid Arthritis: Are we asking enough? A study from Mayo Clinic at ACR Convergence, abstract 1849 examines menopause symptom burden in women with and without RA. Using two research datasets, Kristen Young and colleagues conducted a cross-sectional analysis of https://t.co/V3VJXo3z5w

Beyond HLA-B27: Anti-14-3-3eta Autoantibodies as a Candidate Marker in axSpA 14-3-3 proteins are a conserved family of seven isoforms with diverse cellular functions, found predominantly intracellularly. The 14-3-3eta isoform has been studied as a proinflammatory mediator in RA https://t.co/yC4bhtnTCD

PMR: Spare The Steroids Please Steroids remain both the cornerstone and the Achilles' heel of PMR management. We have aspirations of briskly tapering our patients once they have had their honeymoon phase with prednisone. But when Ms. Jones calls you with a reported second PMR https://t.co/dbrdVZRuoN

All RA-ILD deserves a trial of immunomodulation The optimum treatment approach in RA-ILD remains an area mired in controversy. This is evident from the contrasting views taken by the 2 recent expert guidelines from ACR and EULAR, which advocate for very different treatment https://t.co/vxr8NDruGI

IgG4-RD in 3 Talks: Shorter Steroids, Earlier B-Cell Therapy IgG4-related disease now has two phase 3 trials and its first dedicated treatment guidelines. Glucocorticoids remain the weak point. https://t.co/pWu1eoiMVG https://t.co/yXXk0R4Rbs

New Treatment for Fibromyalgia? Will It Help or Harm? For years, the pharmacologic treatment landscape for fibromyalgia has remained relatively unchanged, with limited therapeutic options despite a substantial disease burden. This condition is characterized by chronic https://t.co/nn9wu7xibY